Completed PHASE2 INTERVENTIONAL 2-arm NCT00391729

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Sponsor: Abbott

Conditions Attention-Deficit/Hyperactivity Disorder

Interventions ABT-089 Placebo

Updated 6 times since 2017 Last updated: Oct 14, 2011 Started: Oct 31, 2006 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Attention-Deficit/Hyperactivity Disorder, this trial is completed. The trial is conducted by Abbott and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bridgewater, United States , Chapel Hill, United States , Charleston, United States , Denver, United States , Farmington Hills, United States , Herndon, United States , Jacksonville, United States , Lafayette, United States , Lake Jackson, United States , Lyndhurst, United States and 13 more locations